×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Arbutus Biopharma Corp. (ABUS) NASDAQ

$2.60 0.11 (4.42%)

Market Cap: $463.09M

As of 03/28/24 04:00 PM EDT. Market closed.

(ABUS)

Arbutus Biopharma Corp. (ABUS)
NASDAQ

$2.60
0.11 (4.42%)

Market Cap: $463.09M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a ... read more

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$556,000
CEO Compensation (Total)
$2.53M
URL
Address
Franklin Atrium, 3015 5 Ave NE Suite 220, Alberta, Calgary, T2A 6T8.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Mark Murray
CEO Compensation (Base)
$556,000
CEO Compensation (Total)
$2.53M
Address
Franklin Atrium, 3015 5 Ave NE Suite 220, Alberta, Calgary, T2A 6T8.
PRICE CHART FOR ARBUTUS BIOPHARMA CORP
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$2.60
Previous Close
$2.49
Days Range
$2.55 - $2.61
52 week range
$1.69 - $3.12
Volume
525,829
Avg. Volume (30 days)
656,618
Market Cap
$463.09M
Dividend Yield
-
P/E
(6.36)
Shares Outstanding
179,492,199
Open
$2.60
Previous Close
$2.49
Days Range
$2.55 - $2.61
52 week range
$1.69 - $3.12
Volume
525,829
Avg. Volume (30 days)
656,618
Market Cap
$463.09M
Dividend Yield
-
P/E
(6.36)
Shares Outstanding
179,492,199
FINANCIAL STATEMENTS FOR ARBUTUS BIOPHARMA CORP
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ARBUTUS BIOPHARMA CORP
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Sims KarenChief Medical OfficerFeb 02, 2024 Sale$2.314,35810,078125,542Feb 05, 2024, 07:55 PM
HASTINGS DAVID CChief Financial OfficerFeb 02, 2024 Sale$2.319,59322,184181,907Feb 05, 2024, 07:54 PM
Sofia Michael J.Chief Scientific OfficerFeb 02, 2024 Sale$2.319,98223,0831,485,121Feb 05, 2024, 07:54 PM
McElhaugh Michael J.Interim President & CEOFeb 02, 2024 Sale$2.3110,16423,5041,504,793Feb 05, 2024, 07:54 PM
Sofia Michael J.Chief Scientific OfficerDec 01, 2021 Sale$5.09200,0001,018,0001,303,403Dec 03, 2021, 04:02 PM
McElhaugh Michael J.Chief Business OfficerFeb 09, 2021 Sale$5.0020,000100,0001,307,457Feb 10, 2021, 05:06 PM
McElhaugh Michael J.Chief Business OfficerDec 14, 2020 Sale$5.0040,000200,0321,337,457Dec 16, 2020, 04:33 PM
McElhaugh Michael J.Chief Business OfficerJul 23, 2020 Sale$5.0120,000100,2001,367,457Jul 27, 2020, 05:27 PM
Murray Mark J.DirectorNov 28, 2018 Option Exercise$1.3525,00033,750341,396Nov 30, 2018, 04:55 PM
Sofia Michael J.Chief Scientific OfficerAug 13, 2018 Sale$9.514,25040,436167,162Aug 15, 2018, 03:14 PM
Sofia Michael J.Chief Scientific OfficerAug 13, 2018 Sale$9.514,25040,4361,499,153Aug 14, 2018, 06:23 PM
Sofia Michael J.Chief Scientific OfficerJul 11, 2018 Sale$10.0010,000100,0001,503,403Jul 13, 2018, 01:36 PM
Sofia Michael J.Chief Scientific OfficerJul 09, 2018 Sale$8.9110,00089,0601,513,403Jul 10, 2018, 01:11 PM
Sofia Michael J.Chief Scientific OfficerJul 06, 2018 Sale$8.4510,00084,5001,523,403Jul 10, 2018, 01:11 PM
Sofia Michael J.Chief Scientific OfficerJul 05, 2018 Sale$8.4010,00084,0001,533,403Jul 06, 2018, 04:05 PM
Sofia Michael J.Chief Scientific OfficerJul 03, 2018 Sale$8.0010,00080,0001,543,403Jul 06, 2018, 04:05 PM
Murray Mark J.President & CEOApr 17, 2018 Option Exercise$0.3527,0079,560316,396Apr 17, 2018, 08:22 PM
Sofia Michael J.Chief Scientific OfficerOct 03, 2017 Sale$8.0010,00080,0001,553,403Oct 05, 2017, 06:34 PM
Sofia Michael J.Chief Scientific OfficerAug 15, 2017 Sale$3.7030,000111,000191,412Aug 17, 2017, 07:41 PM
Abrams Michael J.Managing DirectorAug 16, 2016 Option Exercise$0.3514,1784,89842,097Aug 18, 2016, 06:11 PM
Murray Mark J.President & CEOJun 16, 2016 Option Exercise$2.575,00012,844289,389Jun 20, 2016, 08:33 PM
Murray Mark J.President & CEOSep 11, 2015 Option Exercise$0.44219,42897,514284,389Sep 15, 2015, 04:20 PM
Abrams Michael J.Managing DirectorSep 11, 2015 Option Exercise$0.4417,0447,57427,919Sep 15, 2015, 04:18 PM
HENRIQUES RICHARD C JRDirectorAug 24, 2015 Buy$6.951,0006,9501,000Aug 26, 2015, 01:29 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Sims KarenChief Medical Officer02/02/202410,078
HASTINGS DAVID CChief Financial Officer02/02/202422,184
Sofia Michael J.Chief Scientific Officer02/02/202423,083
McElhaugh Michael J.Interim President & CEO02/02/202423,504
Sofia Michael J.Chief Scientific Officer12/01/20211,018,000
McElhaugh Michael J.Chief Business Officer02/09/2021100,000
McElhaugh Michael J.Chief Business Officer12/14/2020200,032
McElhaugh Michael J.Chief Business Officer07/23/2020100,200
Murray Mark J.Director11/28/201833,750
Sofia Michael J.Chief Scientific Officer08/13/201840,436
Sofia Michael J.Chief Scientific Officer08/13/201840,436
Sofia Michael J.Chief Scientific Officer07/11/2018100,000
Sofia Michael J.Chief Scientific Officer07/09/201889,060
Sofia Michael J.Chief Scientific Officer07/06/201884,500
Sofia Michael J.Chief Scientific Officer07/05/201884,000
Sofia Michael J.Chief Scientific Officer07/03/201880,000
Murray Mark J.President & CEO04/17/20189,560
Sofia Michael J.Chief Scientific Officer10/03/201780,000
Sofia Michael J.Chief Scientific Officer08/15/2017111,000
Abrams Michael J.Managing Director08/16/20164,898
Murray Mark J.President & CEO06/16/201612,844
Murray Mark J.President & CEO09/11/201597,514
Abrams Michael J.Managing Director09/11/20157,574
HENRIQUES RICHARD C JRDirector08/24/20156,950
Load More Insider Transactions
FUNDS WITH A POSITION IN ARBUTUS BIOPHARMA CORP
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.10,390,3000.00066%1.13%Other
GEODE CAPITAL MANAGEMENT, LLC2,817,6950.00074%4.47%Other
AQR CAPITAL MANAGEMENT LLC40,5980.00017%ExitedOther
CHANGE IN SHARES OUTSTANDING FOR ARBUTUS BIOPHARMA CORP
STOCK BUYBACKS FOR ARBUTUS BIOPHARMA CORP
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
0.64%
1Q
12/31/2023
06/30/2023
1.52%
2Q
12/31/2023
03/31/2023
4.29%
3Q
12/31/2023
12/31/2022
8.35%
4Q
12/31/2023
09/30/2022
11.65%
5Q
12/31/2023
06/30/2022
13.33%
6Q
12/31/2023
03/31/2022
13.58%
7Q
12/31/2023
12/31/2021
58.68%
8Q
12/31/2023
09/30/2021
66.44%
9Q
12/31/2023
06/30/2021
74.03%
10Q
12/31/2023
03/31/2021
80.43%
11Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
0.64%
1Q
06/30/2023
1.52%
2Q
03/31/2023
4.29%
3Q
12/31/2022
8.35%
4Q
09/30/2022
11.65%
5Q
06/30/2022
13.33%
6Q
03/31/2022
13.58%
7Q
12/31/2021
58.68%
8Q
09/30/2021
66.44%
9Q
06/30/2021
74.03%
10Q
03/31/2021
80.43%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ARBUTUS BIOPHARMA CORP
LOADING...